Publications
469 results found
Gunn RN, Rabiner EA, 2014, PET neuroimaging: The elephant unpacks his trunk Comment on Cumming: "PET neuroimaging: The white elephant packs his trunk?", NEUROIMAGE, Vol: 94, Pages: 408-410, ISSN: 1053-8119
- Author Web Link
- Cite
- Citations: 2
Guo Q, Owen DR, Rabiner EA, et al., 2014, A graphical method to compare the <i>in vivo</i> binding potential of PET radioligands in the absence of a reference region: application to [<SUP>11</SUP>C]PBR28 and [<SUP>18</SUP>F]PBR111 for TSPO imaging, JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, Vol: 34, Pages: 1162-1168, ISSN: 0271-678X
- Author Web Link
- Cite
- Citations: 31
Colasanti A, Guo Q, Muhlert N, et al., 2014, In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with <SUP>18</SUP>F-PBR111 PET, JOURNAL OF NUCLEAR MEDICINE, Vol: 55, Pages: 1112-1118, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 78
Erritzoe D, Tziortzi A, Bargiela D, et al., 2014, <i>In Vivo</i> Imaging of Cerebral Dopamine D3 Receptors in Alcoholism, NEUROPSYCHOPHARMACOLOGY, Vol: 39, Pages: 1703-1712, ISSN: 0893-133X
- Author Web Link
- Cite
- Citations: 43
Russo E, Khan S, Brown AP, et al., 2014, CORRELATION OF FDG PET SCANNING WITH ENDOSCOPIC FINDINGS IN PATIENTS WITH CROHN'S DISEASE, GUT, Vol: 63, Pages: A74-A74, ISSN: 0017-5749
Kalk NJ, Guo Q, Owen DR, et al., 2014, HIPPOCAMPAL MICROGLIAL DYSFUNCTION IN ALCOHOL DEPENDENCE: A [C-11]PBR28 POSITRON EMISSION TOMOGRAPHY (PET) STUDY, 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism (RSA) / 17th Congress of the International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA), Publisher: WILEY-BLACKWELL, Pages: 23A-23A, ISSN: 0145-6008
- Author Web Link
- Cite
- Citations: 1
Colasanti A, Guo Q, Giannetti P, et al., 2014, TSPO-targeted PET Imaging Suggests Increased Microglia Activation in Multiple Sclerosis Hippocampus is Correlated to Depressive Symptomatology, 69th Annual Scientific Convention and Meeting of the Society-of-Biological-Psychiatry, Publisher: ELSEVIER SCIENCE INC, Pages: 94S-95S, ISSN: 0006-3223
- Author Web Link
- Cite
- Citations: 1
Niccolini F, Marques TR, Haider S, et al., 2014, Brain phosphodiesterase 10A (PDE-10A) density in early premanifest HD gene carriers, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
Searle G, Marques TR, Plisson C, et al., 2014, Kinetic analysis of [<SUP>11</SUP>C]-IMA107, a novel PET radiotracer for PDE10A, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 3
Niccolini F, Marques TR, Haider S, et al., 2014, Brain phosphodiesterase 10A (PDE-10A) density in early premanifest HD gene carriers, 18th International Congress of Parkinson's Disease and Movement Disorders, Publisher: WILEY-BLACKWELL, Pages: S212-S213, ISSN: 0885-3185
Coello C, Wells L, Rabiner E, et al., 2014, Dopaminergic and serotonergic systems imaged across species: Translation of the binding potential, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
Dimber R, Rojas JV, Guo Q, et al., 2014, Imaging brain TSPO availability with [11C]PBR28 PET in patients with retroviral ( HTLV1 and HIV-1) infection, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 1
Plisson C, Weinzimmer D, Jakobsen S, et al., 2014, Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human, JOURNAL OF NUCLEAR MEDICINE, Vol: 55, Pages: 595-601, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 46
Vera J, Guo C, Rabiner I, et al., 2014, Neuroinflammation is evident on cerebral PET imaging using PBR28 in asymptomatic HIV-infected subjects on stable cART, and is associated with pre-treatment plasma HIV RNA, HIV MEDICINE, Vol: 15, Pages: 69-70, ISSN: 1464-2662
Natesan S, Ashworth S, Nielsen J, et al., 2014, Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [<SUP>11C</SUP>]MP-10 PET rodent imaging study with <i>ex vivo</i> confirmation, TRANSLATIONAL PSYCHIATRY, Vol: 4, ISSN: 2158-3188
- Author Web Link
- Open Access Link
- Cite
- Citations: 17
Mick I, Myers J, Stokes P, et al., 2014, Endogenous opioid release in pathological gamblers after an oral amphetamine challenge: a [<SUP>11</SUP>C]carfentanil PET study, ECNP Workshop for Junior Scientists in Europe, Publisher: ELSEVIER SCIENCE BV, Pages: S62-S63, ISSN: 0924-977X
Ridler K, Gunn RN, Searle GE, et al., 2014, Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET, JOURNAL OF PSYCHOPHARMACOLOGY, Vol: 28, Pages: 244-253, ISSN: 0269-8811
- Author Web Link
- Cite
- Citations: 15
Ashworth S, Berges A, Rabiner EA, et al., 2014, Unexpectedly high affinity of a novel histamine H<sub>3</sub> receptor antagonist, GSK239512, <i>in vivo</i> in human brain, determined using PET, BRITISH JOURNAL OF PHARMACOLOGY, Vol: 171, Pages: 1241-1249, ISSN: 0007-1188
- Author Web Link
- Cite
- Citations: 25
Russo E, Khan S, Brown A, et al., 2014, Correlation of FDG PET scanning with clinical and laboratory markers of activity in patients with Crohn's disease, JOURNAL OF CROHNS & COLITIS, Vol: 8, Pages: S167-S168, ISSN: 1873-9946
Owen DR, Guo Q, Kalk NJ, et al., 2014, Eratum: Determination of [ 11 C]PBR28 binding potential in vivo: A first human TSPO blocking study (Journal of Cerebral Blood Flow and Metabolism (2014) 34 (1256)), Journal of Cerebral Blood Flow and Metabolism, Vol: 34, ISSN: 0271-678X
- Cite
- Citations: 3
Jiao J, Searle GE, Tziortzi AC, et al., 2014, Spatio-temporal pharmacokinetic model based registration of 4D PET neuroimaging data, NEUROIMAGE, Vol: 84, Pages: 225-235, ISSN: 1053-8119
- Author Web Link
- Cite
- Citations: 10
Passchier J, Gunn RN, Van Waarde A, 2014, Imaging type 1 glycine transporters in the CNS using positron emission tomography, PET and SPECT of Neurobiological Systems, Pages: 321-330, ISBN: 9783642420139
The type-1 glycine transporter (GlyT1) is a target of interest for the development of new medications for schizophrenia. A specific and selective positron emission tomography (PET) GlyT1 ligand would help understand disease heterogeneity and support drug development studies to determine whether a drug is able to engage this target. During the last 3-4 years, a number of potential ligands have been reported both for preclinical and clinical use. Here, we review the most promising candidates reported to date and make recommendations with regard to their use in clinical studies.
Syvänen S, Gunn RN, 2014, Principles of pet and its role in understanding drug delivery to the brain, AAPS Advances in the Pharmaceutical Sciences Series, Vol: 10, Pages: 213-232, ISSN: 2210-7371
Positron emission tomography (PET) is a non-invasive medical imaging technique that enables the investigation of drug pharmacokinetics in vivo. The technique is especially powerful for pharmacokinetic studies of new CNS drug candidates as tissue samples from the brain are understandably difficult to obtain. The PET technique involves the administration of a radiolabelled molecule whose spatio-temporal distribution can be measured using tomography. The radiolabelled molecule can be the drug under investigation, a structurally different molecule that binds to the same target as the drug candidate or a molecule that interacts with a downstream target that is believed to be affected by the action of the drug candidate. Such radiolabelled probes allow PET to address several questions central for CNS drug development: Does the drug candidate reach the target site? Does the drug candidate interact with the desired target? Is the concentration of the drug at the target site sufficient to illicit an effect? What is the temporal nature of such an interaction? What is the relationship between the target site concentration and the administered dose and/or plasma concentrations?
Gunn R, Rabiner I, 2014, Making drug development visible - and viable, DRUG DISCOVERY TODAY, Vol: 19, Pages: 1-3, ISSN: 1359-6446
- Author Web Link
- Cite
- Citations: 4
Jiao J, Schnabel JA, Gunn RN, 2013, A generalised spatio-temporal registration framework for dynamic PET data: Application to neuroreceptor imaging, Pages: 211-218, ISSN: 0302-9743
This work presents a novel pharmacokinetic model based registration algorithm for the motion correction of dynamic positron emission tomography (PET) images. The algorithm employs a generalised model that derives the input function from the tomographic data itself to model the PET tracer kinetics and thus eliminates the need of arterial blood sampling. Both the temporal constraint from the tracer kinetic behaviour and spatial constraint from the image similarity are integrated in a joint probabilistic model, in which the subject motion and tracer kinetic parameters are iteratively optimised, leading to a groupwise registration framework of motion corrupted dynamic PET data. The algorithm is evaluated with simulated and measured human dopamine D3 receptor imaging data using [11C]-(+)-PHNO. The simulation-based validation demonstrates that the new algorithm has a subvoxel registration accuracy on average for noisy data with simulated motion artefacts. The algorithm also shows reductions in motion on initial experiments with measured clinical [ 11C]-(+)-PHNO brain data. © 2013 Springer-Verlag.
Kalk NJ, Guo Q, Owen DR, et al., 2013, Using Positron Emission Tomography to investigate microglial activation in alcohol dependence: preliminary findings, EUROPEAN NEUROPSYCHOPHARMACOLOGY, Vol: 23, Pages: S122-S122, ISSN: 0924-977X
Colasanti A, Guo Q, Mulhert N, et al., 2013, [18F]PBR111 binding in lesional and peri-lesional multiple sclerosis white matter, 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS, Publisher: SAGE PUBLICATIONS LTD, Pages: 68-69, ISSN: 1352-4585
Guo Q, Colasanti A, Owen DR, et al., 2013, Quantification of the Specific Translocator Protein Signal of18F-PBR111 in Healthy Humans: A Genetic PolymorphismEffect on In Vivo Binding, Journal of Nuclear Medicine, Vol: 54, Pages: 1-9
PET is used to image active inflammatory processes by targetingthe translocator protein (TSPO). In vitro, second-generation TSPOradioligands, such as PBR111, have been shown to bind to humantissue samples with either high affinity (high-affinity binders, HABs),low affinity (low-affinity binders, LABs), or an intermediate, mixedaffinity (mixed-affinity binders, MABs). We previously explainedthese differences in affinity in human tissue via the rs6971 polymorphismin the TSPO gene and predicted that the specific signalfrom PET ligands in vivo would vary accordingly. In silico modelingpredicted that 18F-PBR111 would have a moderate to high specificto-nonspecific ratio in the normal human brain. To test these predictions,we present here the analysis and modeling of 18F-PBR111data in healthy humans. Methods: Twenty-one subjects (9 HABs, 8MABs, and 4 LABs), 28–62 y old, genotyped for the rs6971 polymorphism,underwent 120-min PET scans with arterial samplingafter a bolus injection of 18F-PBR111. Compartmental models andLogan graphical methods enabled estimation of the total volume ofdistribution (VT) in regions of interest (ROIs). To evaluate the specificsignal, we developed 2 methods to estimate the nondisplaceablevolume of distribution (VND): the first assumed that the in vitro affinityratio of 18F-PBR111 in HABs relative to LABs (4-fold) is preserved invivo; the second modeled the difference in the HAB and MAB signalsin the context of an occupancy plot. Results: A 2-tissue-compartmentmodel described the data well, and a significant differencewas found between the VT of HABs, MABs, and LABs across allROIs examined (P , 0.05). We also found a significant correlationbetween VT and age for both HABs and MABs in most ROIs. Theaverage VND estimated by the 2 methods was 1.18 6 0.35 (methodI: VND 5 0.93, method II: VND 5 1.42), implying that the 18F-PBR111BPND was 2.78 6 0.46 in HABs, 1.48 6 0.28 in MABs, and 0.51 60.17 in LABs and that the in vivo affinity ratio was simil
Berges A, Cunningham VJ, Gunn RN, et al., 2013, Non linear mixed effects analysis in PET PK-receptor occupancy studies, NEUROIMAGE, Vol: 76, Pages: 155-166, ISSN: 1053-8119
- Author Web Link
- Cite
- Citations: 3
Comley RA, Salinas CA, Slifstein M, et al., 2013, Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, Vol: 346, Pages: 311-317, ISSN: 0022-3565
- Author Web Link
- Cite
- Citations: 14
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.